DM1-SMe |
| Katalog-Nr.GC18254 |
DM1-SMe ist eine unkonjugierte Form des Maytansinoids in IMGN901. DM1-SMe ist etwa 3- bis 10-mal wirksamer als das Ausgangsarzneimittel Maytansine, mit IC50-Werten im Bereich von 0,003 bis 0,01 nM fÜr DM1-SMe in einer Gruppe menschlicher Tumorzelllinien.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 138148-68-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
DM1-SMe is an analog of mertansine with a thiomethane cap attached to the sulfhydryl group. It has in vitro activity against the pediatric preclinical testing program (PPTP) panel of cancer cell lines with IC50 values of 0.002 to >3 nM.
References:
[1]. Wood, A.C., Maris, J.M., Gorlick, R., et al. Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program Pediatr. Blood Cancer 60(11), 1860-1867 (2013).
Average Rating: 5 (Based on Reviews and 35 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *